Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic or Locally Advanced Unresectable Solid Tumors

Interventions

DRUG: Tuvusertib
DRUG: Lartesertib
DRUG: Avelumab

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]